Optically Active 4-Phenylthiazole Derivative for Oral Thrombopoietin Agonist
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical compositions with low-molecular peptides as thrombopoietin receptor agonists face challenges with oral administration due to poor bioavailability and stability, limiting their effectiveness as platelet production regulators for conditions like thrombocytopenia.
Innovation Solution
A pharmaceutical composition containing an optically active 4-phenylthiazole derivative with specific structural features, exhibiting strong thrombopoietin receptor agonist activity, high oral absorbability, and stability, is developed, which can be administered orally to regulate platelet production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If low-molecular peptides are used as thrombopoietin receptor agonists, then thrombopoietin receptor affinity is improved, but oral bioavailability and stability deteriorate
Solution Approach 1:
The patent changes the chemical structure from peptide-based to small molecule-based (4-phenylthiazole derivative), fundamentally altering the molecular parameters to achieve both high receptor affinity and oral bioavailability. This structural parameter change enables the compound to cross the blood-brain barrier and undergo P-glycoprotein-mediated transport while maintaining thrombopoietin receptor binding activity.
Solution Approach 2:
The patent creates a composite molecular structure combining the thiazole ring system with specific substituent patterns (formula I structure) that integrates multiple functional properties: receptor binding capability, metabolic stability, and oral bioavailability. The composite structure resolves the contradiction by simultaneously incorporating features needed for both high affinity and oral administration.
2Reliability
If peptide derivatives are used for thrombopoietin receptor activation, then receptor binding activity is improved, but oral administrability deteriorates
Solution Approach 1:
The patent replaces the peptide-based molecular mechanism with a small molecule mechanism that can be effectively administered orally. The 4-phenylthiazole derivative uses different molecular interaction mechanisms (aromatic ring stacking, hydrogen bonding patterns) compared to peptide derivatives, enabling oral absorption while maintaining receptor binding activity through alternative molecular recognition pathways.
3Loss of substance
If small molecule compounds are developed for oral administration, then oral bioavailability is improved, but thrombopoietin receptor affinity may deteriorate
Solution Approach 1:
The patent applies local quality by introducing specific substituent groups at defined positions on the 4-phenylthiazole core structure (formula I). The substituents at R1-R6 positions are carefully selected to provide both oral bioavailability properties and high receptor affinity. Specific local modifications like the 2,6-dichloro substitution pattern and various alkyl/alkyloxy groups at different positions optimize both pharmacokinetic and pharmacodynamic properties simultaneously.
Data Source
AI summary
An optically active 4-phenylthiazole derivative having a thrombopoietin receptor agonist activity and a pharmaceutical composition containing the present compound as an active ingredient are created, and a platelet production regulating agent which can be orally administered is provided.Disclosed is a pharmaceutical composition containing, as an active ingredient, an optically active compound represented by the formula:wherein, R1 is a halogen atom or C1-C3 alkyloxy; R2 is C1-C8 alkyl; R3 is C1-C8 alkyl; R4 and R5 are each independently a fluorine atom or chlorine atom; R6 is C1-C3 alkyl or C1-C3 alkyloxy; * indicates that a carbon atom marked with an asterisk is an asymmetric carbon,a pharmaceutically acceptable salt thereof, or a solvate thereof.